New York, NY -- (ReleaseWire) -- 12/27/2012 --Cellceutix Corp (OTCQB: CTIX) 2.42 +0.20 (9.01%) CTIX has been gaining momentum after an article published in the New York Times over the weekend heralded p53 drugs as the new age in cancer research. Leo Ehrlich, CEO of CTIX, said on Monday that he is pleased to see such a high profile article being written on the game changing impact that a p53 drug can have on treating cancers.
Cellceutix Corporation is an early-stage developmental biopharmaceutical company. The Company has acquired exclusive rights to eight different pharmaceutical compound candidates that are designed for treatment of diseases which exist, or may exist in the future.
Find out where CTIX could be headed by getting the free full report here : http://www.wallstreetreport.net/market-scan/?symbol=CTIX
AMARANTUS BIOSCI INC (OTCQB: AMBS) 0.109 +0.033 (43.42%) Amarantus BioScience, Inc. (“Amarantus”) is focused on the discovery and development of therapeutic proteins with the potential to address critically important biological pathways involved in the treatment human diseases. Amarantus BioScience, Inc. (OTCQB: AMBS), a biotechnology company developing treatments and diagnostics for diseases associated with neurodegeneration and apoptosis, today announced the Company has purchased all of the intellectual property (IP) assets from Power3 Medical Products (OTCPK: PWRM). Power3 was in bankruptcy, giving Amarantus the ability to acquire all of Power3’s IP for the diagnosis of multiple neurodegenerative diseases and oncology for $40,000 USD.
Find out more about AMBS here: http://www.wallstreetreport.net/market-scan/?symbol=AMBS
About WallStreetReport.net
WallStreetReport.net issues momentum alerts on stocks that can provide gains to day traders. WallStreetReport.net provides members with timely information and exclusive alerts on cheap and under-valued stocks in the United States with the potential to deliver gains of 100% - 200% or more. WallStreetReport.net monitors and scans the markets for stock related signals as well as any external factors that might bring trading opportunities. Through a vast network of IR professionals WallStreetReport.net is often in the know of several large investor awareness campaigns being deployed.
Timing is everything when trading Penny Stocks. Gain an Edge by joining the WallStreetReport.net newsletter and receiving alerts from a Pro-Active team of researchers. Wall Street Report believes traders should have a chance at successfully trading Penny Stocks and invites traders and investors to be part of the Free VIP membership.
Simply sign up for free and start receiving exclusive alerts.
Subscribe Here: http://www.WallStreetReport.net
Disclosure: WallStreetReport.net is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please visit WallStreetreport.Net website, for complete risks and disclosures.
Contact Info:
Michael Baine
WALL STREET REPORT
info@WallStreetReport.net
347-905-5009